Sign up
Pharma Capital

'About as big as it gets' - VolitionRx's Cameron Reynolds on their US colorectal screening trial

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE:VNRX) tells Proactive that Volition America - their wholly-owned subsidiary - has signed an agreement to participate in a large multi-centre clinical study with the Great Lakes New England Clinical Validation Centre.

The study will provide around 13,500 samples of people aged 50 or over who have not previously undergone screening or a diagnostic colonoscopy.

Already 4,677 samples have been collected and up to 9,000 will be prospectively collected.

 

View full VNRX profile

VolitionRx Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.